title: Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists.
abstract: This article reviews the effects of estradiol (E(2)), progesterone (P) and P receptor antagonists (PA) on the rhesus macaque endometrium. Ovariectomized macaques can be treated with implants of estradiol (E(2)) and P to induce precisely controlled, artificial menstrual cycles. During these cycles, treatment with E(2) alone induces an artificial proliferative phase marked by extensive endometrial epithelial cell proliferation and increased expression of stromal and epithelial estrogen receptor (ER) and P receptor (PR). Androgen receptor (AR) is also upregulated by E(2) but is expressed only by the endometrial stroma. Progesterone acts on the E(2) primed endometrium to induce secretory differentiation and causes suppression of epithelial and stromal ER, epithelial PR, and stromal AR in the functionalis zone. However, epithelial ER and PR are retained in the basalis zone during the secretory phase. When potent P antagonists (PA) are administered acutely at the end of an E(2) + P induced cycle, menses typically ensues similar to P withdrawal at the end of the menstrual cycle. When PAs are administered chronically there is significant blockage of all P- dependent effects including upregulation of ER, PR and AR and suppression of glandular secretory function. However, chronic PA administration also inhibits estrogen-dependent endometrial cell proliferation and growth. This endometrial antiproliferative effect is the basis of the clinical use of PA to control various diseases such as endometriosis.
authors.affiliation: Division of Reproductive Sciences, Oregon National Primate Research Center, 505 NW 185th Ave, Beaverton, OR 97006, USA. slaydeno@ohsu.edu
authors.forename: Ov D
authors.initials: OD
authors.lastname: Slayden
authors.forename: Robert M
authors.initials: RM
authors.lastname: Brenner
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D004343:Drug Implants; D004357:Drug Synergism; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism*; D004847:Epithelial Cells / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008253:Macaca mulatta / Q000378:metabolism*; D008597:Menstrual Cycle / Q000187:drug effects / Q000378:metabolism; D008600:Menstruation-Inducing Agents / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D010052:Ovariectomy; D011374:Progesterone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011944:Receptors, Androgen / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D004343:Drug Implants; D008600:Menstruation-Inducing Agents; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol